{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:53:49Z","timestamp":1792029229969,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"30","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["Equipe labellis\u00e9e Ligue Contre le Cancer 2016"],"award-info":[{"award-number":["Equipe labellis\u00e9e Ligue Contre le Cancer 2016"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["Equipe labellis\u00e9e Ligue Contre le Cancer 2016"],"award-info":[{"award-number":["Equipe labellis\u00e9e Ligue Contre le Cancer 2016"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-LABX-0028-01"],"award-info":[{"award-number":["ANR-11-LABX-0028-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006331","name":"Cancerop\u00f4le PACA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41388-019-0848-9","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T10:03:06Z","timestamp":1561716186000},"page":"5873-5889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)\/NF-\u03baB signaling pathway"],"prefix":"10.1038","volume":"38","author":[{"given":"M.","family":"Rathore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ohanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ben Jouira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Larbret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9409-2588","authenticated-orcid":false,"given":"S.","family":"Audebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Montaudi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Prod\u2019Homme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tartare-Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-559X","authenticated-orcid":false,"given":"M.","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"key":"848_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc3218","volume":"12","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012;12:349\u201361.","journal-title":"Nat Rev Cancer"},{"key":"848_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","volume":"14","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14:455\u201367.","journal-title":"Nat Rev Cancer"},{"key":"848_CR3","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1158\/0008-5472.CAN-14-1174","volume":"74","author":"K Kemper","year":"2014","unstructured":"Kemper K, de Goeje PL, Peeper DS, van Amerongen R. Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Res. 2014;74:5937\u201341.","journal-title":"Cancer Res."},{"key":"848_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1755-148X.2012.00986.x","volume":"25","author":"DS Widmer","year":"2012","unstructured":"Widmer DS, Cheng PF, Eichhoff OM, Belloni BC, Zipser MC, Schlegel NC, et al. Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell Melanoma Res. 2012;25:343\u201353.","journal-title":"Pigment Cell Melanoma Res."},{"key":"848_CR5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1038\/onc.2011.425","volume":"31","author":"Y Cheli","year":"2012","unstructured":"Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene. 2012;31:2461\u201370.","journal-title":"Oncogene."},{"key":"848_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7683","volume":"6","author":"A Verfaillie","year":"2015","unstructured":"Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G, et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun. 2015;6:6683.","journal-title":"Nat Commun"},{"key":"848_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6712","volume":"5","author":"J Muller","year":"2014","unstructured":"Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712.","journal-title":"Nat Commun"},{"key":"848_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546:431\u20135.","journal-title":"Nature"},{"key":"848_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040378","volume":"7","author":"N Fenouille","year":"2012","unstructured":"Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS ONE. 2012;7:e40378.","journal-title":"PLoS ONE"},{"key":"848_CR10","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1158\/0008-5472.CAN-12-1033","volume":"72","author":"MB Weiss","year":"2012","unstructured":"Weiss MB, Abel EV, Mayberry MM, Basile KJ, Berger AC, Aplin AE. TWIST1 is an ERK1\/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res. 2012;72:6382\u201392.","journal-title":"Cancer Res."},{"key":"848_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccr.2013.08.018","volume":"24","author":"J Caramel","year":"2013","unstructured":"Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer cell 2013;24:466\u201380.","journal-title":"Cancer cell"},{"key":"848_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7993","volume":"6","author":"M Tichet","year":"2015","unstructured":"Tichet M, Prod\u2019Homme V, Fenouille N, Ambrosetti D, Mallavialle A, Cerezo M, et al. Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. Nat Commun. 2015;6:6993.","journal-title":"Nat Commun"},{"key":"848_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coi.2015.11.002","volume":"38","author":"C Garlanda","year":"2016","unstructured":"Garlanda C, Jaillon S, Doni A, Bottazzi B, Mantovani APTX3. a humoral pattern recognition molecule at the interface between microbe and matrix recognition. Curr Opin Immunol. 2016;38:39\u201344.","journal-title":"Curr Opin Immunol"},{"key":"848_CR14","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.jhep.2016.02.029","volume":"64","author":"B Bottazzi","year":"2016","unstructured":"Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016;64:1416\u201327.","journal-title":"J Hepatol."},{"key":"848_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.cell.2015.01.004","volume":"160","author":"E Bonavita","year":"2015","unstructured":"Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015;160:700\u201314.","journal-title":"Cell."},{"key":"848_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.molmed.2016.04.007","volume":"22","author":"E Magrini","year":"2016","unstructured":"Magrini E, Mantovani A, Garlanda C. The dual complexity of PTX3 in health and disease: a balancing act? Trends Mol Med. 2016;22:497\u2013510.","journal-title":"Trends Mol Med"},{"key":"848_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973\u20137.","journal-title":"Nature"},{"key":"848_CR18","doi-asserted-by":"publisher","first-page":"16028","DOI":"10.1038\/celldisc.2016.28","volume":"2","author":"B Titz","year":"2016","unstructured":"Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, et al. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov. 2016;2:16028.","journal-title":"Cell Discov."},{"key":"848_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trecan.2015.07.009","volume":"1","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Massague J. Surviving at a distance: organ-specific metastasis. Trends Cancer. 2015;1:76\u201391.","journal-title":"Trends Cancer."},{"key":"848_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/CMR.0000000000000021","volume":"23","author":"YR Na","year":"2013","unstructured":"Na YR, Lee JS, Lee SJ, Seok SH. Interleukin-6-induced Twist andx N-cadherin enhance melanoma cell metastasis. Melanoma Res. 2013;23:434\u201343.","journal-title":"Melanoma Res."},{"key":"848_CR21","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.4049\/jimmunol.1400814","volume":"193","author":"S Bozza","year":"2014","unstructured":"Bozza S, Campo S, Arseni B, Inforzato A, Ragnar L, Bottazzi B, et al. PTX3 binds MD-2 and promotes TRIF-dependent immune protection in aspergillosis. J Immunol. 2014;193:2340\u20138.","journal-title":"J Immunol."},{"key":"848_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1600-0625.2008.00701.x","volume":"17","author":"JH Ahn","year":"2008","unstructured":"Ahn JH, Park TJ, Jin SH, Kang HY. Human melanocytes express functional Toll-like receptor 4. Exp Dermatol. 2008;17:412\u20137.","journal-title":"Exp Dermatol."},{"key":"848_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00403-012-1300-y","volume":"305","author":"N Eiro","year":"2013","unstructured":"Eiro N, Ovies C, Fernandez-Garcia B, Alvarez-Cuesta CC, Gonzalez L, Gonzalez LO, et al. Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. Arch Dermatol Res. 2013;305:59\u201367.","journal-title":"Arch Dermatol Res."},{"key":"848_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1620\/tjem.234.57","volume":"234","author":"Y Takazawa","year":"2014","unstructured":"Takazawa Y, Kiniwa Y, Ogawa E, Uchiyama A, Ashida A, Uhara H, et al. Toll-like receptor 4 signaling promotes the migration of human melanoma cells. Tohoku J Exp Med. 2014;234:57\u201365.","journal-title":"Tohoku J Exp Med."},{"key":"848_CR25","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1158\/1535-7163.MCT-13-0487","volume":"12","author":"R Ronca","year":"2013","unstructured":"Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, et al. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. Mol Cancer Ther. 2013;12:2760\u201371.","journal-title":"Mol Cancer Ther."},{"key":"848_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep29385","volume":"6","author":"TH Ying","year":"2016","unstructured":"Ying TH, Lee CH, Chiou HL, Yang SF, Lin CL, Hung CH, et al. Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells. Sci Rep. 2016;6:29385.","journal-title":"Sci Rep"},{"key":"848_CR27","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.18632\/oncotarget.3482","volume":"6","author":"WC Chang","year":"2015","unstructured":"Chang WC, Wu SL, Huang WC, Hsu JY, Chan SH, Wang JM, et al. PTX3 gene activation in EGF-induced head and neck cancer cell metastasis. Oncotarget. 2015;6:7741\u201357.","journal-title":"Oncotarget."},{"key":"848_CR28","doi-asserted-by":"crossref","first-page":"41364","DOI":"10.18632\/oncotarget.17326","volume":"8","author":"SH Chan","year":"2017","unstructured":"Chan SH, Tsai JP, Shen CJ, Liao YH, Chen BK. Oleate-induced PTX3 promotes head and neck squamous cell carcinoma metastasis through the up-regulation of vimentin. Oncotarget. 2017;8:41364\u201378.","journal-title":"Oncotarget."},{"key":"848_CR29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1158\/0008-5472.CAN-11-3123","volume":"72","author":"CW Li","year":"2012","unstructured":"Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 2012;72:1290\u2013300.","journal-title":"Cancer Res."},{"key":"848_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1333215","volume":"6","author":"M Rubino","year":"2017","unstructured":"Rubino M, Kunderfranco P, Basso G, Greco CM, Pasqualini F, Serio S, et al. Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer. Oncoimmunology. 2017;6:e1333215.","journal-title":"Oncoimmunology."},{"key":"848_CR31","first-page":"2663","volume":"35","author":"B Choi","year":"2015","unstructured":"Choi B, Lee EJ, Park YS, Kim SM, Kim EY, Song Y, et al. Pentraxin-3 silencing suppresses gastric cancer-related inflammation by inhibiting chemotactic migration of macrophages. Anticancer Res. 2015;35:2663\u20138.","journal-title":"Anticancer Res"},{"key":"848_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11060-016-2168-z","volume":"129","author":"JN Tung","year":"2016","unstructured":"Tung JN, Ko CP, Yang SF, Cheng CW, Chen PN, Chang CY, et al. Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo. J Neurooncol. 2016;129:201\u20139.","journal-title":"J Neurooncol."},{"key":"848_CR33","doi-asserted-by":"publisher","first-page":"eaah4674","DOI":"10.1126\/scisignal.aah4674","volume":"10","author":"C Thomas","year":"2017","unstructured":"Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, et al. Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Sci Signal. 2017;10:eaah4674.","journal-title":"Sci Signal."},{"key":"848_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbcan.2017.11.004","volume":"1869","author":"A Giacomini","year":"2018","unstructured":"Giacomini A, Ghedini GC, Presta M, Ronca R. Long pentraxin 3: a novel multifaceted player in cancer. Biochim Biophys Acta, Rev Cancer. 2018;1869:53\u201363.","journal-title":"Biochim Biophys Acta, Rev Cancer"},{"key":"848_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.4181","volume":"230","author":"R Ronca","year":"2013","unstructured":"Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, et al. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. J Pathol. 2013;230:228\u201338.","journal-title":"J Pathol."},{"key":"848_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2015.07.002","volume":"28","author":"R Ronca","year":"2015","unstructured":"Ronca R, Giacomini A, Di Salle E, Coltrini D, Pagano K, Ragona L, et al. Long-pentraxin 3 derivative as a small-molecule fgf trap for cancer therapy. Cancer Cell. 2015;28:225\u201339.","journal-title":"Cancer Cell."},{"key":"848_CR37","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1158\/1535-7163.MCT-11-0286","volume":"10","author":"D Leali","year":"2011","unstructured":"Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, et al. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther. 2011;10:1600\u201310.","journal-title":"Mol Cancer Ther."},{"key":"848_CR38","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1593\/neo.09934","volume":"11","author":"F Margheri","year":"2009","unstructured":"Margheri F, Serrati S, Lapucci A, Anastasia C, Giusti B, Pucci M, et al. Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice. Neoplasia. 2009;11:1106\u201315.","journal-title":"Neoplasia."},{"key":"848_CR39","first-page":"649","volume":"28","author":"FQ Hu","year":"2014","unstructured":"Hu FQ, Qiao T, Xie X, Hu R, Xiao HB. Knockdown of the inflammatory factor pentraxin-3 suppresses growth and invasion of lung adenocarcinoma through the AKT and NF-kappa B pathways. J Biol Regul Homeost Agents. 2014;28:649\u201357.","journal-title":"J Biol Regul Homeost Agents."},{"key":"848_CR40","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1158\/1078-0432.CCR-10-3024","volume":"17","author":"EP Diamandis","year":"2011","unstructured":"Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17:2395\u20139.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res."},{"key":"848_CR41","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14:5198\u2013208.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"848_CR42","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/bjc.2013.348","volume":"109","author":"S Kondo","year":"2013","unstructured":"Kondo S, Ueno H, Hosoi H, Hashimoto J, Morizane C, Koizumi F, et al. Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. Br J Cancer. 2013;109:739\u201346.","journal-title":"Br J Cancer."},{"key":"848_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/jvh.12472","volume":"23","author":"RF Carmo","year":"2016","unstructured":"Carmo RF, Aroucha D, Vasconcelos LR, Pereira LM, Moura P, Cavalcanti MS. Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. J Viral Hepat. 2016;23:116\u201322.","journal-title":"J Viral Hepat."},{"key":"848_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jneuroim.2013.04.009","volume":"260","author":"M Locatelli","year":"2013","unstructured":"Locatelli M, Ferrero S, Martinelli Boneschi F, Boiocchi L, Zavanone M, Maria Gaini S, et al. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J Neuroimmunol. 2013;260:99\u2013106.","journal-title":"J Neuroimmunol."},{"key":"848_CR45","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/pros.20966","volume":"69","author":"L Ravenna","year":"2009","unstructured":"Ravenna L, Sale P, Di Vito M, Russo A, Salvatori L, Tafani M, et al. Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate. 2009;69:1245\u201355.","journal-title":"Prostate."},{"key":"848_CR46","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137.","journal-title":"Nature"},{"key":"848_CR47","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri1703","volume":"5","author":"M Karin","year":"2005","unstructured":"Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749\u201359.","journal-title":"Nat Rev Immunol"},{"key":"848_CR48","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/jid.2015.91","volume":"135","author":"Y Shao","year":"2015","unstructured":"Shao Y, Le K, Cheng H, Aplin AE. NF-kappaB regulation of c-FLIP promotes TNFalpha-mediated RAF inhibitor resistance in melanoma. J Invest Dermatol. 2015;135:1839\u201348.","journal-title":"J Invest Dermatol."},{"key":"848_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9755","volume":"6","author":"S Riesenberg","year":"2015","unstructured":"Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, et al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015;6:8755.","journal-title":"Nat Commun"},{"issue":"7","key":"848_CR50","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/1535-7163.MCT-17-0919","volume":"17","author":"Robin Didier","year":"2018","unstructured":"Didier R, Mallavialle A, Ben Jouira R, Domdom MA, Tichet M, Auberger P, et al. Targeting the proteasome-associated deubiquitinating enzyme USP14 impairs melanoma cell survival and overcomes resistance to MAPK-targeting therapies. Mol Cancer Ther. 2018;17:1416\u201329.","journal-title":"Molecular Cancer Therapeutics"},{"key":"848_CR51","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/0008-5472.CAN-08-2690","volume":"69","author":"O Bailet","year":"2009","unstructured":"Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, Gonthier N, et al. Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res. 2009;69:2748\u201356.","journal-title":"Cancer Res."},{"key":"848_CR52","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1158\/0008-5472.CAN-05-3189","volume":"66","author":"G Robert","year":"2006","unstructured":"Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E, et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res. 2006;66:7516\u201323.","journal-title":"Cancer Res."},{"key":"848_CR53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1755-148X.2010.00790.x","volume":"24","author":"N Fenouille","year":"2011","unstructured":"Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S, et al. Thep53\/p21(Cip1\/ Waf1) pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res. 2011;24:219\u201332.","journal-title":"Pigment Cell Melanoma Res."},{"key":"848_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508:118\u201322.","journal-title":"Nature"},{"key":"848_CR55","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1101\/gad.305854.117","volume":"32","author":"M Ohanna","year":"2018","unstructured":"Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G, et al. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Genes Dev. 2018;32:448\u201361.","journal-title":"Genes Dev"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0848-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0848-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0848-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:16:25Z","timestamp":1684602985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-019-0848-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":55,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1038\/s41388-019-0848-9","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]},"assertion":[{"value":"25 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}